Akebia Therapeutics, Inc. (AKBA) Investor Relations Documents

Akebia Therapeutics, Inc. (AKBA) investor relations documents from the company's IR site: 40 press releases. Read in-app with summaries. First-party data.

Investor relations documents — source: company IR site
PublishedTypeDocument
2026-08-05Press releasePress release
2026-08-05Press releaseAkebia Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights
2026-08-03Press releasePress release
2026-08-03Press releasePress release
2026-08-03Press releaseAkebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-08-03Press releaseAkebia Therapeutics Announces Initiation of a Phase 2 Basket Trial to Study Ebribafusp, a Next-Generation Complement Inh
2026-07-29Press releasePress release
2026-07-29Press releaseAkebia Therapeutics to Report Second Quarter 2026 Financial Results and Discuss Recent Business Highlights
2026-06-30Press releasePress release
2026-06-10Press releasePress release
2026-06-10Press releaseAkebia Therapeutics Strengthens Vafseo® (vadadustat) Patent Portfolio
2026-06-07Press releasePress release
2026-06-07Press releasePress release
2026-06-07Press releasePress release
2026-06-07Press releasePress release
2026-06-07Press releasePress release
2026-06-07Press releasePress release
2026-06-07Press releasePress release
2026-06-07Press releasePress release
2026-06-06Press releasePress release
2026-06-06Press releasePress release
2026-06-06Press releasePress release
2026-06-06Press releasePress release
2026-06-06Press releasePress release
2026-06-06Press releasePress release
2026-06-06Press releasePress release
2026-06-06Press releasePress release
2026-06-06Press releasePress release
2026-06-06Press releasePress release
2026-06-06Press releasePress release
2026-05-28Press releaseAkebia Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference
2026-05-07Press releaseAkebia Therapeutics Reports First Quarter 2026 Financial Results and Commercial and Pipeline Highlights
2026-05-04Press releaseAkebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-05-04Press releaseAkebia Therapeutics Announces Vadadustat Post-hoc Win Statistics Analysis Demonstrating Statistically Significant Reduct
Press releaseAkebia Therapeutics to Report First Quarter 2026 Financial Results and Discuss Recent Business Highlights
2026-04-13Press releaseAkebia Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of AKB-9090
2026-04-07Press releaseAkebia Therapeutics to Conduct Investor Meetings at the Raymond James 2026 Biotech Innovation Symposium
2026-04-02Press releaseAkebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-04-01Press releaseAkebia Therapeutics Appoints Biopharmaceutical Leader Philip Vickers, Ph.D. to its Board of Directors
2026-03-19Press releaseAkebia Therapeutics to Host Virtual R&D Day Highlighting Robust Kidney Disease Pipeline, on April 2, 2026

AKBA overview · AKBA earnings · AKBA financials · AKBA KPIs · AKBA ownership · AKBA peers · AKBA filings

Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.